Blair Grubb, MD
Cardiovascular Disease · Toledo, OHNPI 1386638211
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $3,200 of the $3,946 with a category attached, or 81.1%. Biotronik Inc. accounts for 83.7% of it on its own, with 8 other manufacturers making up the rest. Reporting peaked in 2019 at $2,080 and has fallen 97.0% since, to $63 in 2025.
Across 27 payments — averaging $146.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Biotronik Inc.$3K
- Kestra Medical Technology Services, Inc.$340
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$105
- Heartflow, Inc.$75
- Abiomed$63
- Novartis$20
- plus $43 from 3 others
What the payments were for
- Speaking & faculty fees$3,20081%
- Food & beverage$74619%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Biotronik Inc. | 6 | $3,302 |
| Kestra Medical Technology Services, Inc. | 5 | $340 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 8 | $105 |
| Heartflow, Inc. | 2 | $75 |
| Abiomed | 2 | $63 |
| Novartis | 1 | $20 |
| Inari Medical, Inc. | 1 | $20 |
| E.r. Squibb & Sons, L.L.C. | 1 | $12 |
| Cook Medical LLC | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,946 in reported general payments places this provider in the 70th percentile of 827 cardiovascular disease providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CorlanorIvabradine Hcl | 180 | $194,629 |
| Droxidopa | 25 | $52,334 |
| EliquisApixaban | 41 | $47,029 |
| Ivabradine Hcl | 68 | $44,456 |
| Midodrine Hcl | 171 | $26,020 |
| XareltoRivaroxaban | 15 | $16,261 |
| Modafinil | 26 | $11,526 |
| Pyridostigmine Bromide | 130 | $10,543 |
| Pyridostigmine Bromide ErPyridostigmine Bromide | 18 | $8,689 |
| Desmopressin Acetate | 51 | $5,394 |
| Bupropion XlBupropion Hcl | 132 | $3,272 |
| Clonidine | 44 | $3,143 |
| Nebivolol Hcl | 45 | $2,948 |
| Fludrocortisone Acetate | 60 | $2,146 |
| Ranolazine ErRanolazine | 41 | $2,111 |
Paid to pharmacies, not to this prescriber.
Other cardiovascular disease in Toledo
- Rajendra KattarToledo$37K
- Guilherme AttizzaniCleveland$1.3M
- Gregory LamCircleville$428K
- Emil HayekHudson$379K
- Abraham LincoffCleveland$369K
- Oussama WazniCleveland$367K
- Ian NeelandCleveland$329K
- Kamal ShemisaCincinnati$314K
- Mehdi ShishehborElyria$237K
- Abdu HawwaGarfield Hts$234K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.